Skip to main content
. 2022 Apr 20;14(9):2061. doi: 10.3390/cancers14092061

Figure 4.

Figure 4

The clinical performance of cfDNA for predicting the survival outcomes: Kaplan–Meier survival analysis for (A) recurrence, (B) marginal recurrence, (C) multifocal recurrence, and (D) overall survival of TACE-treated patients. Univariate Cox regression analysis of the serum and plasma biomarkers for (E) TACE-treated and (F) non-treated patients.